205 related articles for article (PubMed ID: 11705308)
1. Clobetasol propionate foam, 0.05%.
Melian EB; Spencer CM; Jarvis B
Am J Clin Dermatol; 2001; 2(2):89-92; discussion 93. PubMed ID: 11705308
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
Lebwohl M; Sherer D; Washenik K; Krueger GG; Menter A; Koo J; Feldman SR
Int J Dermatol; 2002 May; 41(5):269-74. PubMed ID: 12100701
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
Gottlieb AB; Ford RO; Spellman MC
J Cutan Med Surg; 2003; 7(3):185-92. PubMed ID: 12704534
[TBL] [Abstract][Full Text] [Related]
5. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
6. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
Andres P; Poncet M; Farzaneh S; Soto P
J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery.
Franz TJ; Parsell DA; Myers JA; Hannigan JF
Int J Dermatol; 2000 Jul; 39(7):535-8. PubMed ID: 10940121
[No Abstract] [Full Text] [Related]
8. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis.
Kircik LH; Eastman WJ; Gwazdauskas J
J Drugs Dermatol; 2013 Mar; 12(3):328-34. PubMed ID: 23545917
[TBL] [Abstract][Full Text] [Related]
10. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis.
Mazzotta A; Esposito M; Carboni I; Schipani C; Chimenti S
J Dermatolog Treat; 2007; 18(2):84-7. PubMed ID: 17520464
[TBL] [Abstract][Full Text] [Related]
11. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
12. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
Reygagne P; Mrowietz U; Decroix J; de Waard-van der Spek FB; Acebes LO; Figueiredo A; Caputo R; Poncet M; Arsonnaud S
J Dermatolog Treat; 2005 Feb; 16(1):31-6. PubMed ID: 15897165
[TBL] [Abstract][Full Text] [Related]
13. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
Jarratt M; Breneman D; Gottlieb AB; Poulin Y; Liu Y; Foley V
J Drugs Dermatol; 2004; 3(4):367-73. PubMed ID: 15303780
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of clobetasol propionate in different vehicles.
Franz TJ; Lehman PA; Feldman SR; Spellman MC
Skin Pharmacol Appl Skin Physiol; 2003; 16(4):212-6. PubMed ID: 12784060
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Guenther L; Tan J; Lynde C; Kerrouche N; Villemagne H;
Cutis; 2010 Jan; 85(1):43-50. PubMed ID: 20184211
[TBL] [Abstract][Full Text] [Related]
16. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
[TBL] [Abstract][Full Text] [Related]
17. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis.
Feldman SR; Ravis SM; Fleischer AB; McMichael A; Jones E; Kaplan R; Shavin J; Weiss J; Bartruff JK; Levin DL; Del Rosso J; Kpea N
J Cutan Med Surg; 2001; 5(5):386-9. PubMed ID: 11907847
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
19. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.
Gordon ML
Clin Ther; 1998; 20(1):26-39. PubMed ID: 9522102
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.
Olsen EA; Cram DL; Ellis CN; Hickman JG; Jacobson C; Jenkins EE; Lasser AE; Lebwohl M; Leibsohn E; Medansky RS
J Am Acad Dermatol; 1991 Mar; 24(3):443-7. PubMed ID: 2061442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
